Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015		Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities
Net earnings	$ 5,144		$ 1,774	$ 4,128
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	417		383	388
Amortization of intangible assets	419		403	509
Stock-based compensation	282		241	212
Upfront costs and milestones related to collaborations	280		1,102	338
Other, net	489		434	34
Changes in operating assets and liabilities, net of acquisitions:
Accounts and other receivables	(1,076)		(172)	681
Inventories	(434)		(203)	(56)
Prepaid expenses and other assets	511		(220)	459
Accounts payable and other liabilities	1,503		(193)	(426)
Cash flows from operating activities	7,535	[1]	3,549	6,267
Cash flows from investing activities
Acquisitions of Pharmacyclics, Inc., net of cash acquired	(11,488)
Other acquisitions and investments	(964)		(622)	(405)
Acquisitions of property and equipment	(532)		(612)	(491)
Purchases of investment securities	(851)		(1,169)	(930)
Sales and maturities of investment securities	880		1,477	2,705
Other	19
Cash flows from investing activities	(12,936)		(926)	879
Cash flows from financing activities
Net change in short-term borrowings	(19)		12	(601)
Proceeds from issuance of long-term debt	20,660
Repayments of long-term debt and capital leases	(4,018)		(17)
Debt issuance cost	(182)		(141)
Dividends paid	(3,294)		(2,661)	(2,555)
Purchases of treasury stock	(7,567)		(652)	(320)
Proceeds from the exercise of stock options	142		225	347
Net transactions with Abbott Laboratories, excluding non-cash items				(247)
Other, net	30		(59)	(66)
Cash flows from financing activities	5,752		(3,293)	(3,442)
Effect of exchange rate changes on cash and equivalents	(300)		(577)	(10)
Net increase (decrease) in cash and equivalents	51		(1,247)	3,694
Cash and equivalents, beginning of period	8,348		9,595	5,901
Cash and equivalents, end of period	8,399		8,348	9,595
Supplemental Schedule of Non-Cash Investing and Financing Activities
Issuance of common stock associated with the acquisition of Pharmacyclics, Inc.	8,405
Other supplemental information
Interest paid, net of portion capitalized	536		419	283
Income taxes paid	$ 1,108		$ 498	$ 1,305

[1] Cash flows from operating activities included the impact of transaction and financing-related and other costs incurred in connection with the terminated proposed combination with Shire plc. Refer to Note 5 for additional information.